It has established a multidisciplinary bioimaging service system to speed up and efficiency of new drug development and has a image-based PK/PD evaluation, pharmacological evaluation, and validation platform, providing life-cycle bioimaging services through customized modeling.
Equipment and techniques
* Marked radioactive drugs are determined whether to proceed or not after sufficient discussion with the PET core room.
|
TYPE OF IMAGING |
Classification |
Target/Mechanism |
|
Optical (evaluation of tumor size and treatment effect) |
Evaluation of cancer transition and treatment effects through bioluminescence imaging |
|
|
Efficacy evaluation of drug by imaging cell death |
||
|
Nuclear medicine, PET(metabolic and functional evaluation of tumors |
[18F]FDG | Glucose metabolism |
| [18F]FLT * | DNA replication | |
| [18F]FMISO * | Hypoxia | |
| [18F]FES * | Estrogen receptor | |
| [18F]FDOPA/[18F]FET * | Amino acid metabolism | |
| [68Ga]DOTATOC | Somatostatin receptor | |
|
Magnetic resonance, MRI (tumor size and function evaluation) |
T1w/T2w/PD | Lesion imaging of Solid tumor, Measurement of T1/T2/T2* mapping-Volume |
| DWI | Diffusion weighted imaging , Tissue/Cellularity 측정 | |
| DCE, DSC, FAIR | Dynamic Contrast Enhanced, Dynamic Susceptibility Contrast Blood flow (Angiogenetic imaging) | |
| 1H MR spectroscopy | Metabolic imaging | |
Service
- Customized test design
- in vitro/in vivo/ex vivo imaging
- Tumor growth inhibition test
- MOA & POC verification
- PD/PK evaluation based on fluorescence imaging
- Immunoprofiling
- Evaluation of tumor microenvironment with multiplex IHC
Service example (tumor follow-up observation using imaging)
- Animal : Mouse
[Chemical induced hepatocellular carcinoma] - 9.4T MRI[Acial, T2w Images]
- Monitoring for 5 months (Tumor growth]
Liver cancer imaging using MRI
[18F]FDG, MC38 model
Before treatment
After treatment
Optical imaging of lung metastases